The efficacy of drugs targeting the B-cell receptor signaling pathway has invigorated the enthusiasm to molecularly identify lymphoma subcategories that offer unique therapeutic opportunities.

Some antigenic stimuli may result in lymphoid proliferations that exhibit worrisome cytoarchitectural features but do not fulfill the full criteria for the diagnosis of lymphoma – that is ...